Share Name Share Symbol Market Type Share ISIN Share Description
Empyrean LSE:EME London Ordinary Share GB00B09G2351 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.38p +2.89% 13.53p 13.30p 13.76p 13.53p 13.15p 13.15p 896,511 09:01:05
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Oil & Gas Producers 0.0 -10.5 -3.7 - 53.98

Empyrean (EME) Latest News

More Empyrean News
Empyrean Takeover Rumours

Empyrean (EME) Share Charts

1 Year Empyrean Chart

1 Year Empyrean Chart

1 Month Empyrean Chart

1 Month Empyrean Chart

Intraday Empyrean Chart

Intraday Empyrean Chart

Empyrean (EME) Discussions and Chat

Empyrean Forums and Chat

Date Time Title Posts
16/1/201809:34EME - Post Sale of Sugarloaf Asset14,772
19/6/201718:26EMPYREAN ENERGY (EME): CHART AND DISCUSSION THREAD (moderated)46,106
29/9/201521:27Empyrean Energy22,096
09/12/201409:14WHY HAVE THE AGM SO QUICKLY?27

Add a New Thread

Empyrean (EME) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Empyrean trades in real-time

Empyrean (EME) Top Chat Posts

Empyrean Daily Update: Empyrean is listed in the Oil & Gas Producers sector of the London Stock Exchange with ticker EME. The last closing price for Empyrean was 13.15p.
Empyrean has a 4 week average price of 10.13p and a 12 week average price of 10.13p.
The 1 year high share price is 30.75p while the 1 year low share price is currently 2.75p.
There are currently 398,995,110 shares in issue and the average daily traded volume is 1,537,463 shares. The market capitalisation of Empyrean is £52,866,852.08.
showme01: Starting to see a bit of strength in EME share price. Onwards and upwards.
showme01: Expect a bit of volatility here over Xmas. SGC closed down 10.7% on only 0.5% of shares in issue traded. I don't expect EME to follow the same drop as we have a spread of assets but the MM will play games especially over a quiet trading period the next couple of weeks. I think nerves must be getting the better of some at SGC and no doubt some here especially the ones that jumped onto a rising share price. Personally, I'm not at all bothered with the swings in share price. I'm delighted to have got back in at a price I never thought I would see as I was prepared to pay upwards of 20p a share once my SIPP transfer came through. I'm here for one reason only, China. Indonesia and California are bonuses. California could still prove to be a massive bonus but it is no longer priced in at this level imo. Gaz Bisht and Tom Kelly could not hide their enthusiasm for this China project when I met them earlier this year at the GM. Tom thought their chances of getting the China deal was 1 in 100. The Chinese initially turned them down as EME were far too small. Gaz and Tom did a great selling job on them and I think reading between the lines, Gaz had built up a very good relationship with them over the years at a previous company. Since meeting them, the RNS info on China is very positive and I did not want to miss out on this potentially huge prize. Wishing all here a great Christmas (apart from windup merchant Brimsley) and 2018 should be a very prosperous year for us all (including Brimsley as he can only have one motive and that is to drive the share price down) :-)
seagreen: Standard AIM regulation procedure when volatility in a share price occurs is to ring the Nomad and insist on an explanation of such volatility. The Nomad is then duty bound to request the corporate to explain any volatility in the share price as soon as possible. If the corporate does not have any meaningful explanation they are duty bound to say so. If there is no RNS issued from EME it is reasonable to assume they have no additional material information that they are aware of to explain the current stock girations. When they do have such information they are duty bound to issue it to the market be it good or bad immediately to protect the integrity of the AIM market. If in fact the volatility is being caused by opportunistic traders capitalising on the silence that is not a RNS advent. This leaves EME with only one alternative to issue a "we are not aware of any reason behind the recent decline in the share price etc...". However, they wont issue a statement saying we believe or we think or perhaps the share price movement has been caused by margin traders or T20 traders overtrading which due to the delay has caused forced selling as that is not factual it is theoretical. I have no information be it positive or negative but I can assure you having worked in the environment a senior member of AIM reg will be in daily contact with EME's Nomad asking for a regular update as they strive to protect the reputation of the AIM market for orderly trading and transparancy. It may be no coincindences that about T15 ago the price was trading at around 22p and some will have been caught with their trunks down as the tide turns.
starzerus: Soaring small-cap stocks Empyrean Energy plc and Motif Bio plc could make you seriously rich Oil and gas explorer Empyrean Energy (LSE: EME) and clinical-stage biopharmaceutical company Motif Bio (LSE: MTFB) are two of the most exciting small-caps on the UK market today. They are also among the most volatile, with their share prices spiking in recent months, only to slip in recent days. Companies like these could make you seriously rich, but you must also understand the risks. Cooking with gas Empyrean is pursuing what it describes as “three cornerstone assets with transformational potential,” the Block 29/11 offshore field in China, Duyung PSC offshore Indonesia, and a multi-project participating interest in the Sacramento Basin, California. At the start of November it had the distinction of being a 12-bagger over 12 months, fuelled by positive seismic data at its China prospect, better-than-expected reservoir quality in Indonesia, and several zones of high gas flows in Dempsey, Sacramento. However, it has slipped due to profit-taking and a disappointing release on 15 November showing that the lowest zone in Sacramento is “sub-commercial” at current gas prices. However, significant gas flows suggests shallower zones could offer more encouraging results. Empyrean strikes back Oil investors must be constantly braced for potential setbacks like this one. Dempsey still offers a potential 1trn cubic feet, which local surface infrastructure could quickly bring to market. Recent slippage might even be your opportunity to buy into this £60m AIM-listed explorer. Oil prices are rising, Empyrean has an experienced industry team behind it, and also boasts a net cash position. It is definitely one to monitor to see whether the share price fails lower as short-term investors drift away. There could be a cheaper buying opportunity ahead, if you are feeling brave, but there are also other exciting prospects out there. Infectious bacteria Motif Bio went off like a bullet following publication of its half-yearly report on 29 September, its share price leaping 50% in a week to peak at 45p by 6 October. This was down to positive top-line results from REVIVE-1, a global Phase 3 clinical trial of its investigational drug candidate iclaprim in patients with acute bacterial skin and skin structure infections. However, the AIM-listed stock has also since trailed away and today languishes at around 31p. This £82m company is a clinical-stage biopharmaceutical specialist that develops novel antibiotics to treat patients with serious infections caused by multi-drug resistant bacteria. You can see the opportunities, and of course, the threats. As with Empyrean, future revenues, profits and stock market performance will be driven by news flow, so brace yourselves. Pipeline progress Recent news, such as announcing positive topline results for its REVIVE-2 treatment, presenting new pre-clinical data on iclaprim and securing up to US$20m in debt financing in mid-November have not prevented the downwards drift. However, this is a small company aiming at a big juicy target, and if its treatments come through the pipeline, you can expect its share price to spiral. Or you might prefer this pharmaceutical opportunity. Both these companies are trading at roughly half their 52-week highs to make them an exciting opportunity for those happy to embrace volatility rather than run away from it.
starzerus: The last few months have been hugely encouraging for investors in Empyrean Energy (LSE: EME). The oil and gas exploration company has released a series of positive news updates concerning the progress it is making in delivering its strategy. This has caused investor sentiment to improve sharply, which has contributed to a 1300% share price rise during the last year. Looking ahead, it would not be surprising for this trend to continue. Interest in the oil and gas industry continues to increase, and this could help to push the company’s share price higher over the medium term. Improving sentiment With the oil price moving to its highest level since 2015, investor sentiment towards a range of oil and gas companies has improved in recent months. While in Empyrean Energy’s case its recent news has largely been responsible for its stunning share price gains, a rising oil price could mean that its valuation rises to an even higher level in future. Certainly, there is likely to be higher volatility in the oil price. There is great uncertainty about whether OPEC will continue with its supply cut, as well as how non-OPEC producers will react to a rising oil price. However, leading producers such as Saudi Arabia and Russia seem to be keen on supporting the oil price in future. As well as this, increasing demand levels, which have reduced the supply surplus of recent years, are thus far showing little sign of slowing down. This could catalyse the oil price in future. Furthermore, Empyrean seems to have a relatively sound financial position. It raised $1m in August of this year. With it having a net cash position, it appears to have the financial strength to deliver on its strategy. This could make investors more positive towards the stock, since a net cash position indicates that its risk profile may be lower than for a number of other oil and gas exploration companies. Diversification While a rising oil price may continue, it may also be prudent for investors to diversify into other assets. The gold price has also enjoyed a positive 2017, and gold miners such as Avesoro (LSE: ASO) have prospered this year. In fact, the company’s share price has gained 37% in the year-to-date, and quarterly results released on Monday showed it is making good progress with its strategy. For example, gold production in the quarter to 30 September increased by 26% versus the prior quarter. This helped to boost revenue by 32% on the year, while adjusted EBITDA (earnings before interest, tax, depreciation and amortisation) increased fivefold versus the second quarter level. This figure was boosted by an EBITDA margin of 21%, which was up predominantly due to reduced operating cash costs per ounce and an increase in the realised gold price. Looking ahead, both Avesoro and Empyrean Energy could offer further share price growth. The two companies seem to have highly enticing risk/reward ratios at the present time. Top growth stock
petercrosby: I like palindromic EME share prices.
twaintwix: Magnum I believe are spudding Tulainlo next week. I found the report while doing a search but lost it again. Isn't EME connected to that gas field as well? The drill will boost EME share price if successful. The report mentioned $6B dollars to the Magnum syndicate if successful.
bushman1: Safiande, nailing your colours to the mast, where do you see a commercial discovery at Dempsey taking the SGC and EME share prices ?
tidy 2: Ref 11 tcfThese are the facts that make this a multi multi bagger from these levels and knocks spots off other O&G stocks for upside and almost immediate production. Talking multi TCF and each of them worth 57p to Eme share price.
kevjames: The problem for EME is cash generation or lack of! There is no cash currently coming in from China or Duyung, but the future potential is huge. Therefore, Dempsey is the only project that offers EME a potential quick inject of cash, but only if the gas flows at commercial rates. That is why Tom probably sees this as a good move. The downside to Dempsey is that it has cost us $2 million already and a slug more will be needed to put it into production. However, if we get to put it into production, it would be at this point that I would do a placing at 15, 16p or whatever and it should be limited to shareholders who were holding the day before any big announcement on commercial flows. This would be a key event - proving the play to commercial production would be a game changer. That would then lead to stage 2, the Alvares well ( hopefully sidetrack so only a couple of million rather than $8million). From that, possibly more fundraising will be needed in the 20's to see out the 3 Dempsey AMI wells. Then onto China and Duyung :-) However, if Dempsey is unsuccessful, I doubt the other drills will happen, simply due to the lack of funds. Clearly This outcome would impact the EME share price, but we still have the other two projects to underpin, so share price should still be around 8p. However, Tom and his team will need to live on beans for a while - Toon could you arrange that!! That said, keep an eye on the Tulainyo well (no EME WI) that is due to spud in Sept - that will also be a good indicator of how good the deep plays really are in the north basin and if they are really worth chasing. Next drill update should be interesting, should cover the first 2 or maybe 3 primary targets. Above AIMHO. Hopefully some good news soon for the LTHs.
Empyrean share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20180116 09:58:07